Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-HS Long-Term Extension
NL-OMON60084Phase 3Completed
- Sponsor
- Incyte
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of povorcitinib in hidradenitis suppurativa (HS), sponsored by Incyte. Primary endpoint: Proportion of participants with treatment-emergent adverse events. Started Nov 2024; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON60084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60084.